<DOC>
	<DOCNO>NCT02251678</DOCNO>
	<brief_summary>Elorac , Inc. evaluate effect Elimune™ capsule biomarkers C-reactive protein ( CRP ) , Tumor Necrosis Factor ( αTNF ) , Interleuken-2 ( IL-2 ) , Interleuken-6 ( IL-6 ) , Interleuken-12 ( IL-12 ) subject plaque psoriasis without arthritis . Psoriasis chronic inflammatory skin disease polygenic predisposition combine trigger factor trauma , inflammation medication . Elimune™ uniquely formulate prescription dietary supplement oral administration . Each capsule contain proprietary blend natural ingredient , Vitamin D3 , Folic Acid , Nicotinamide , Eicosapentaenoic Acid , Doscosahexaenoic Acid , Quercetin , Curcumin , Glycyrrhizin , Hesperetin , share anti-inflammatory activity include ability inhibit tumor necrosis factor-α ( TNF-α ) .</brief_summary>
	<brief_title>Evaluate Effect Elimune Capsules</brief_title>
	<detailed_description>This open-label study consist 1 day Screening Period 28 day Treatment Period . During Screening Period subject sign inform consent eligibility determine review inclusion/exclusion criterion include history plaque psoriasis . Demographics , medical history , medication history , height weight record . A blood sample pre-dose biomarker analysis collect . Subjects take two Elimune capsule twice daily Day 1 Day 28 . On Day 7 Day 28 subject return site provide blood sample biomarker analysis . Adverse event concomitant medication record throughout study . A Physician 's Evaluation Plaque Severity Physician 's Evaluation Arthritis Severity perform Day 1 , Day 7 , Day 28 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Subject voluntarily agree participate study sign IRBapproved inform consent prior perform screen procedure . 2 . Males female least 18 year age . 3 . Except plaque psoriasis without arthritis , subject generally good health . 4 . Subject exhibit acutely active least moderate severe plaquetype psoriasis ( &gt; 5 % BSA ) without arthritis . 5 . Nonpregnant , nonlactating female childbearing potential agree use medically acceptable form birth control ( abstinence , hormonal contraceptive , diaphragm spermicide , condom spermicide , intrauterine device ) throughout study female nonchildbearing potential ( surgically sterile [ hysterectomy bilateral tubal ligation ] postmenopausal ≥ 1 year ) . A negative urine pregnancy test must confirm screen female subject surgically sterile . 6 . Nonsmokers ( nicotine use ) determine history ( nicotine use past year ) . 7 . Subject willing able cooperate extent require protocol . 1 . Subject know allergy hypersensitivity Vitamin D3 , Folic Acid , Nicotinamide , Eicosapentaenoic Acid , Doscosahexaenoic Acid , Quercetin , Curcumin , Glycyrrhizin , Hesperetin . 2 . Subject history alcohol and/or illicit drug abuse . 3 . Female subject pregnant breastfeeding . 4 . History use immunosuppressant product ( e.g . Enbrel , Remicade , Humira ) within 12 month Day 1 . 5 . Use oral corticosteroid , methotrexate , cyclosporine , ultraviolet light , Soriatane 90 Days prior Day 1 throughout trial . 6 . Use counter ( OTC ) medication ( include vitamin ) , prescription medication , herbal remedy stable 30 day prior Day 1 stable throughout study . 7 . Use investigational drug within 90 day prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Plaque</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>CRP</keyword>
	<keyword>αTNF</keyword>
	<keyword>Interleuken</keyword>
</DOC>